帕金森病长期个性化自适应脑深部电刺激:一项非随机临床试验
这项国际、开放标签、前瞻性关键试验纳入68例既往持续DBS稳定的帕金森病患者,评估长期居家自适应DBS(aDBS)的耐受性、疗效与安全性。结果显示DT-aDBS组91%、ST-aDBS组79%达到主要终点性能目标,ST-aDBS较cDBS降低TEED约15%,长期aDBS耐受良好且安全。
要点
- 长期居家aDBS在既往cDBS稳定的帕金森病患者中耐受良好、有效且安全。
- DT-aDBS组91%、ST-aDBS组79%达到主要终点性能目标,两种模式间无差异。
- ST-aDBS较cDBS平均降低TEED约15%,与DT-aDBS无差异。
核心结论
- 在既往持续DBS稳定的帕金森病患者中,长期aDBS耐受良好、有效且安全。
研究设计与样本
- 国际、开放标签、前瞻性关键试验,2020年12月至2022年7月在美国、加拿大和欧洲入组68例帕金森病患者。
- 耐受2种aDBS模式者随机盲法各30天交叉(单盲交叉设计),仅耐受1种模式者仅评估该模式,评估期间药物保持稳定。
- 参与者可选继续所选aDBS模式长期随访10个月,分析数据截至2024年3月,缺失超过5%时采用多重插补。
主要发现
- DT-aDBS组91%的参与者、ST-aDBS组79%的参与者达到主要终点性能目标,两种aDBS模式间无差异(χ21=1.0;P=.51)。
- ST-aDBS较cDBS降低TEED(平均变化-15%;名义P=.01),与DT-aDBS无差异。
- 除1例刺激相关不良事件外,其余均在aDBS设置和调整阶段缓解,长期随访中无严重器械不良事件。
- 探索性分析提示DT-aDBS较cDBS改善无麻烦性异动症的on-time。
关键数值与推荐
- 主要终点要求至少50%的参与者达到性能目标:与cDBS相比,aDBS期间自报运动日记中无麻烦性异动症的on-time减少不低于1个SD(事后阈值减少小于2小时/天)。
- 次要终点为比较aDBS与cDBS的总电能量输出(TEED)。
临床怎么用
- 对于既往持续DBS稳定的帕金森病患者,可考虑长期居家aDBS治疗。
- ST-aDBS可能有助于降低总电能量输出,两种aDBS模式均可选择。
局限性
- 开放标签设计,主要终点基于自报运动日记。
- 样本量68例,长期随访10个月,探索性分析结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Adaptive deep brain stimulation (aDBS) automatically adjusts stimulation amplitude in response to changes in relevant neural activity in people with Parkinson disease (PD). Whether long-term at-home aDBS is safe and delivers effective therapy in people with PD remains unknown. OBJECTIVE: To determine the tolerability, efficacy, and safety of long-term aDBS in people with PD who were previously stable receiving continuous DBS (cDBS). DESIGN, SETTING, AND PARTICIPANTS: This international, open-label, prospective, pivotal trial enrolled participants from December 2020 to July 2022 in the US, Canada, and Europe. Referred participants with PD were first assessed while receiving stable cDBS and those who tolerated 2 aDBS modes were randomized and blinded to 30 days in each mode (single-blind crossover design); those who tolerated only 1 mode were assessed in that mode only; assessments completed holding medication stable. Participants were given the option to continue their selected mode of aDBS for long-term follow-up (10 months). Data used for analysis were from March 2024. Multiple imputation was used if more than 5% of data was missing for the primary or secondary end points. A referred sample of 68 participants with PD, stable while receiving cDBS and medication, was included. INTERVENTIONS: Two modes of aDBS controlled by an embedded closed-loop stimulation system: single threshold (ST-aDBS) and dual threshold (DT-aDBS). MAIN OUTCOMES AND MEASURES: The primary end point required that at least 50% of participants meet a performance goal of on-time (ie, time when symptoms were well controlled) without troublesome dyskinesias with no less than 1-SD reduction (and post hoc threshold less than 2 hours per day reduction) reported during aDBS therapy compared to cDBS, determined from a self-reported motor diary. The secondary end point was total electrical energy delivered (TEED) compared between aDBS and cDBS. Safety assessments were conducted by characterizing adverse events (AEs), stimulation-related AEs, serious AEs, and device deficiencies. RESULTS: A total of 68 participants enrolled (mean [SD] age, 62.2 [8.4] years; 48 [70.6%] male); 40 and 35 were evaluated with DT-aDBS and ST-aDBS, respectively. The primary end point performance goal was met in the DT-aDBS group (91% of participants) and ST-aDBS (79% of participants) with the post hoc performance threshold; no difference between aDBS modes (χ21 = 1.0; P = .51). TEED was reduced during ST-aDBS compared to cDBS (mean change, -15%; nominal P = .01) and not different from DT-aDBS. All but 1 stimulation-related AE resolved during the aDBS setup and adjustment phase with no serious device AEs through long-term follow-up. Exploratory analyses suggested improvement in on-time without troublesome dyskinesias with DT-aDBS compared to cDBS. CONCLUSIONS AND RELEVANCE: In this study, long-term aDBS was tolerable, effective, and safe in people with PD who were previously stable while receiving cDBS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04547712.
引用
- Bronte-Stewart HM, Beudel M, Ostrem JL, et al. Long-Term Personalized Adaptive Deep Brain Stimulation in Parkinson Disease: A Nonrandomized Clinical Trial. JAMA Neurol. 2025. PMID: 40982287. doi:10.1001/jamaneurol.2025.2781
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。